Microbot Medical Inc. 8-K

What Happened
Microbot Medical Inc. (MBOT) announced on May 26, 2026 that it received regulatory approval from the Israeli Ministry of Health’s AMAR Division to market and commercialize the LIBERTY® Endovascular Robotic System in Israel. The company furnished a press release reporting the approval as Exhibit 99.1 to its Form 8‑K filed the same day.

Key Details

• Approval date reported: May 26, 2026 (announcement/filed on Form 8‑K).
• Regulator: Israeli Ministry of Health, AMAR Division (medical device authority).
• Scope: Authorization to market and commercialize the LIBERTY Endovascular Robotic System in Israel.
• Additional benefit: Approval enables Microbot to obtain a Free Sale Certificate to support submissions and commercial activities in other jurisdictions.
• Disclosure type: Regulation FD disclosure and Other Events (Items 7.01 and 8.01); press release filed as Exhibit 99.1.

Why It Matters
This is a regulatory milestone that legally permits Microbot to sell and promote its LIBERTY robotic system in Israel and can streamline regulatory submissions abroad via a Free Sale Certificate. For investors, the approval removes a regulatory barrier to commercial activity in Israel—potentially enabling local sales, clinical use, and related revenue—though the filing does not include financial projections or sales figures. Watch for follow-up announcements about commercialization plans, distribution, pricing, and any reported sales or orders.